CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region
PURPOSE: We aimed to evaluate the feasibility and clinical effectiveness of CT-guided 125I brachytherapy for distant oral and maxillofacial metastases. MATERIALS AND METHODS: We retrospectively analyzed 65 patients with 84 distant oral and maxillofacial metastases. Thirty-one patients with 38 lesion...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-02-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523316302157 |
| _version_ | 1819095137542733824 |
|---|---|
| author | Huzheng Yan Zhanwang Xiang Zhihui Zhong Zhiqiang Mo Tao Zhang Guanyu Chen Fujun Zhang Fei Gao |
| author_facet | Huzheng Yan Zhanwang Xiang Zhihui Zhong Zhiqiang Mo Tao Zhang Guanyu Chen Fujun Zhang Fei Gao |
| author_sort | Huzheng Yan |
| collection | DOAJ |
| description | PURPOSE: We aimed to evaluate the feasibility and clinical effectiveness of CT-guided 125I brachytherapy for distant oral and maxillofacial metastases. MATERIALS AND METHODS: We retrospectively analyzed 65 patients with 84 distant oral and maxillofacial metastases. Thirty-one patients with 38 lesions received 125I brachytherapy (group A) and 34 with 46 lesions received external beam radiotherapy (EBRT; group B). RESULTS: Median follow-up time was 16 months. The 3-, 6-, 12-, 18-, and 24-month local control rates for group A were 83.9%, 75.9%, 66.7%, 38.4%, and 25.0%, respectively; for group B they were 76.5%, 62.5%, 43.8%, 25.0%, and 0.0%, respectively (P < .05); the median local tumor progression-free survival times were 14 and 9 months, respectively. Group A had a better local tumor progression-free survival (LTPFS) relative to group B (P < .001; HR, 6.961 [95%CI, 2.109, 9.356]). Cox proportional hazards regression analysis indicated that 125I brachytherapy, tumor size, and primary pathological type were the independent factors affecting LTPFS. Additionally, 125I brachytherapy showed better performance in relieving patient clinical symptoms relative to EBRT (P < .05). Group A also had fewer complications than group B, especially regarding grade 3/4 complications according to Radiation Therapy Oncology Group grading criteria. Mean overall survival times in groups A and B were 17.1 and 14.8 months, respectively. CONCLUSION: CT-guided 125I brachytherapy is feasible and safe for distant oral and maxillofacial metastases; it achieved a better local control rate, longer LTPFS and fewer complications without compromising overall survival compared with EBRT. |
| first_indexed | 2024-12-21T23:38:31Z |
| format | Article |
| id | doaj.art-9d1f4ac8f61c413c83a1879ce9ad4b6a |
| institution | Directory Open Access Journal |
| issn | 1936-5233 1944-7124 |
| language | English |
| last_indexed | 2024-12-21T23:38:31Z |
| publishDate | 2017-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-9d1f4ac8f61c413c83a1879ce9ad4b6a2022-12-21T18:46:17ZengElsevierTranslational Oncology1936-52331944-71242017-02-01101909810.1016/j.tranon.2016.11.007CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial regionHuzheng YanZhanwang XiangZhihui ZhongZhiqiang MoTao ZhangGuanyu ChenFujun ZhangFei GaoPURPOSE: We aimed to evaluate the feasibility and clinical effectiveness of CT-guided 125I brachytherapy for distant oral and maxillofacial metastases. MATERIALS AND METHODS: We retrospectively analyzed 65 patients with 84 distant oral and maxillofacial metastases. Thirty-one patients with 38 lesions received 125I brachytherapy (group A) and 34 with 46 lesions received external beam radiotherapy (EBRT; group B). RESULTS: Median follow-up time was 16 months. The 3-, 6-, 12-, 18-, and 24-month local control rates for group A were 83.9%, 75.9%, 66.7%, 38.4%, and 25.0%, respectively; for group B they were 76.5%, 62.5%, 43.8%, 25.0%, and 0.0%, respectively (P < .05); the median local tumor progression-free survival times were 14 and 9 months, respectively. Group A had a better local tumor progression-free survival (LTPFS) relative to group B (P < .001; HR, 6.961 [95%CI, 2.109, 9.356]). Cox proportional hazards regression analysis indicated that 125I brachytherapy, tumor size, and primary pathological type were the independent factors affecting LTPFS. Additionally, 125I brachytherapy showed better performance in relieving patient clinical symptoms relative to EBRT (P < .05). Group A also had fewer complications than group B, especially regarding grade 3/4 complications according to Radiation Therapy Oncology Group grading criteria. Mean overall survival times in groups A and B were 17.1 and 14.8 months, respectively. CONCLUSION: CT-guided 125I brachytherapy is feasible and safe for distant oral and maxillofacial metastases; it achieved a better local control rate, longer LTPFS and fewer complications without compromising overall survival compared with EBRT.http://www.sciencedirect.com/science/article/pii/S1936523316302157 |
| spellingShingle | Huzheng Yan Zhanwang Xiang Zhihui Zhong Zhiqiang Mo Tao Zhang Guanyu Chen Fujun Zhang Fei Gao CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region Translational Oncology |
| title | CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region |
| title_full | CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region |
| title_fullStr | CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region |
| title_full_unstemmed | CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region |
| title_short | CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region |
| title_sort | ct guided 125i brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region |
| url | http://www.sciencedirect.com/science/article/pii/S1936523316302157 |
| work_keys_str_mv | AT huzhengyan ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT zhanwangxiang ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT zhihuizhong ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT zhiqiangmo ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT taozhang ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT guanyuchen ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT fujunzhang ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion AT feigao ctguided125ibrachytherapyinthetreatmentofdistantmetastasesintheoralcavityandmaxillofacialregion |